709 related articles for article (PubMed ID: 27385177)
81. OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker.
Nakagomi-Hagihara R; Nakai D; Kawai K; Yoshigae Y; Tokui T; Abe T; Ikeda T
Drug Metab Dispos; 2006 May; 34(5):862-9. PubMed ID: 16501004
[TBL] [Abstract][Full Text] [Related]
82. Modeling approach for multiple transporters-mediated drug-drug interactions in sandwich-cultured human hepatocytes: effect of cyclosporin A on hepatic disposition of mycophenolic acid phenyl-glucuronide.
Matsunaga N; Suzuki K; Nakanishi T; Ogawa M; Imawaka H; Tamai I
Drug Metab Pharmacokinet; 2015 Apr; 30(2):142-8. PubMed ID: 25989889
[TBL] [Abstract][Full Text] [Related]
83. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview.
Schinkel AH; Jonker JW
Adv Drug Deliv Rev; 2003 Jan; 55(1):3-29. PubMed ID: 12535572
[TBL] [Abstract][Full Text] [Related]
84. Hepatic basolateral efflux contributes significantly to rosuvastatin disposition I: characterization of basolateral versus biliary clearance using a novel protocol in sandwich-cultured hepatocytes.
Pfeifer ND; Yang K; Brouwer KL
J Pharmacol Exp Ther; 2013 Dec; 347(3):727-36. PubMed ID: 24023367
[TBL] [Abstract][Full Text] [Related]
85. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans.
Kivistö KT; Niemi M
Pharm Res; 2007 Feb; 24(2):239-47. PubMed ID: 17177112
[TBL] [Abstract][Full Text] [Related]
86. Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers.
Liu L; Cui Y; Chung AY; Shitara Y; Sugiyama Y; Keppler D; Pang KS
J Pharmacol Exp Ther; 2006 Jul; 318(1):395-402. PubMed ID: 16627748
[TBL] [Abstract][Full Text] [Related]
87. In Vitro Assessment of the Drug-Drug Interaction Potential of Verinurad and Its Metabolites as Substrates and Inhibitors of Metabolizing Enzymes and Drug Transporters.
Gopaul VS; Vildhede A; Andersson TB; Erlandsson F; Lee CA; Johansson S; Hilgendorf C
J Pharmacol Exp Ther; 2021 Aug; 378(2):108-123. PubMed ID: 34074714
[TBL] [Abstract][Full Text] [Related]
88. Clinical Relevance of Hepatic and Renal P-gp/BCRP Inhibition of Drugs: An International Transporter Consortium Perspective.
Taskar KS; Yang X; Neuhoff S; Patel M; Yoshida K; Paine MF; Brouwer KLR; Chu X; Sugiyama Y; Cook J; Polli JW; Hanna I; Lai Y; Zamek-Gliszczynski M;
Clin Pharmacol Ther; 2022 Sep; 112(3):573-592. PubMed ID: 35612761
[TBL] [Abstract][Full Text] [Related]
89. Genetic polymorphisms of human hepatic OATPs: functional consequences and effect on drug pharmacokinetics.
Nie Y; Yang J; Liu S; Sun R; Chen H; Long N; Jiang R; Gui C
Xenobiotica; 2020 Mar; 50(3):297-317. PubMed ID: 31180267
[TBL] [Abstract][Full Text] [Related]
90. [A review on regulation of drug transporters during inflammation].
Zeng H; Bi HC; Huang M
Yao Xue Xue Bao; 2011 Jul; 46(7):773-9. PubMed ID: 22010345
[TBL] [Abstract][Full Text] [Related]
91. Human efflux transport of testosterone, epitestosterone and other androgen glucuronides.
Järvinen E; Kidron H; Finel M
J Steroid Biochem Mol Biol; 2020 Mar; 197():105518. PubMed ID: 31704245
[TBL] [Abstract][Full Text] [Related]
92. Emerging transporters of clinical importance: an update from the International Transporter Consortium.
Hillgren KM; Keppler D; Zur AA; Giacomini KM; Stieger B; Cass CE; Zhang L;
Clin Pharmacol Ther; 2013 Jul; 94(1):52-63. PubMed ID: 23588305
[TBL] [Abstract][Full Text] [Related]
93. Prediction of pharmacokinetics and drug-drug interactions when hepatic transporters are involved.
Li R; Barton HA; Varma MV
Clin Pharmacokinet; 2014 Aug; 53(8):659-78. PubMed ID: 25056496
[TBL] [Abstract][Full Text] [Related]
94. Novel Screening System for Biliary Excretion of Drugs Using Human Cholangiocyte Organoid Monolayers with Directional Drug Transport.
Mizoi K; Okada R; Mashimo A; Masuda N; Itoh M; Ishida S; Yamazaki D; Ogihara T
Biol Pharm Bull; 2024; 47(2):427-433. PubMed ID: 38369341
[TBL] [Abstract][Full Text] [Related]
95. Multiple transport systems mediate the hepatic uptake and biliary excretion of the metabolically stable opioid peptide [D-penicillamine2,5]enkephalin.
Hoffmaster KA; Zamek-Gliszczynski MJ; Pollack GM; Brouwer KL
Drug Metab Dispos; 2005 Feb; 33(2):287-93. PubMed ID: 15528320
[TBL] [Abstract][Full Text] [Related]
96. Transporter-enzyme interplay and the hepatic drug clearance: what have we learned so far?
Alluri RV; Li R; Varma MVS
Expert Opin Drug Metab Toxicol; 2020 May; 16(5):387-401. PubMed ID: 32228316
[No Abstract] [Full Text] [Related]
97. Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver.
Chu X; Korzekwa K; Elsby R; Fenner K; Galetin A; Lai Y; Matsson P; Moss A; Nagar S; Rosania GR; Bai JP; Polli JW; Sugiyama Y; Brouwer KL;
Clin Pharmacol Ther; 2013 Jul; 94(1):126-41. PubMed ID: 23588320
[TBL] [Abstract][Full Text] [Related]
98. Intestinal and Hepatocellular Transporters: Therapeutic Effects and Drug Interactions of Herbal Supplements.
Stieger B; Mahdi ZM; Jäger W
Annu Rev Pharmacol Toxicol; 2017 Jan; 57():399-416. PubMed ID: 27648763
[TBL] [Abstract][Full Text] [Related]
99. Impact of basolateral multidrug resistance-associated protein (Mrp) 3 and Mrp4 on the hepatobiliary disposition of fexofenadine in perfused mouse livers.
Tian X; Swift B; Zamek-Gliszczynski MJ; Belinsky MG; Kruh GD; Brouwer KL
Drug Metab Dispos; 2008 May; 36(5):911-5. PubMed ID: 18276836
[TBL] [Abstract][Full Text] [Related]
100. Successful Prediction of Human Hepatic Concentrations of Transported Drugs Using the Proteomics-Informed Relative Expression Factor Approach.
Yin M; Balhara A; Marie S; Tournier N; Gáborik Z; Unadkat JD
Clin Pharmacol Ther; 2024 Mar; 115(3):595-605. PubMed ID: 38037845
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
